Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keynote-151: Pembrolizumab in Chinese Melanoma
NCT02821000Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2016
- Primary completion
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in melanoma, sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced At Least One Adverse Event at 17 months, Number of Participants Who Discontinued Study Treatment Due to an AE at 17 months and 1 more. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02821000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821000.